drugset / Trial / NCT00068614

HER-2 Protein Vaccine in Treating Women With Breast Cancer

NCT00068614 ↗

Open-labelTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of HER-2 protein vaccine in treating women who have breast cancer.

Timeline

Start
2003-07
Primary completion
2005-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AutoVac™ Vaccine — Intramuscular

Indications